Servicio de Neurología, Clinical Neuroscience Research Group, IRBLleida-Hospital Universitari Arnau de Vilanova, Spain.
Unitat Trastorns Cognitius, Clinical Neuroscience Research Group, IRBLleida-Hospital Universitari Santa Maria Lleida, Spain.
J Alzheimers Dis. 2018;64(2):543-549. doi: 10.3233/JAD-180234.
Hallucinations may have a broad spectrum and include so-called minor hallucinations (MHs). MHs include passage hallucinations (PHs), visual illusions, and presence hallucinations (PrHs).
To determine the prevalence and characteristics of MHs in Alzheimer's disease (AD) and amnestic mild cognitive impairment (aMCI) patients, and to describe their potential relationship with cognition, behavioral symptoms, and use of psychoactive drugs.
We have recruited prospectively and consecutively 268 subjects (90 AD mild-moderate drug-naïve patients, 78 aMCI, and 100 controls). All patients responded to a semi-structured questionnaire in order to rate psychotic phenomena. Clinical, neuropsychological, and demographic data of patients with and without MH were compared with those of age, sex, and education-matched controls.
The prevalence of MHs was 21.1% (19) in AD, 12.8% (10) in aMCI, and 3% (3) in controls (p < 0.01). The most frequent MH was PrH (9.3%), followed by PH (4.9%) and illusion (0.7%). Eight (27.8%) patients had more than one MH. After adjusting for age and gender, there was a negative correlation between the presence of MHs and MMSE score (r = -0.261; p < 0.01) and a positive correlation between MHs and Neuropsychiatric Inventory score (r = 0.237; p < 0.01). We did not observe a significant relationship between presence of MHs and the consumption of psychoactive drugs (p > 0.05).
We have shown that the presence of MHs in patients with newly diagnosed, untreated AD and aMCI is more than controls. MHs were correlated with other behavioral symptoms and a worse cognitive performance. We suggest the specific interrogation for MHs as a clinical feature for this population.
幻觉可能具有广泛的谱,包括所谓的轻度幻觉 (MHs)。MHs 包括幻觉 (PHs)、视觉错觉和存在幻觉 (PrHs)。
确定阿尔茨海默病 (AD) 和遗忘型轻度认知障碍 (aMCI) 患者中 MHs 的患病率和特征,并描述它们与认知、行为症状和精神活性药物使用的潜在关系。
我们前瞻性地连续招募了 268 名受试者 (90 名 AD 轻度至中度未经药物治疗的患者、78 名 aMCI 和 100 名对照)。所有患者都回答了一份半结构化问卷,以评估精神病现象。比较了有和没有 MH 的患者的临床、神经心理学和人口统计学数据与年龄、性别和教育匹配的对照组的数据。
AD 患者 MHs 的患病率为 21.1%(19 例),aMCI 患者为 12.8%(10 例),对照组为 3%(3 例)(p < 0.01)。最常见的 MH 是 PrH(9.3%),其次是 PH(4.9%)和错觉(0.7%)。8 名患者(27.8%)有多种 MH。在调整年龄和性别后,MHs 的存在与 MMSE 评分呈负相关(r = -0.261;p < 0.01),与神经精神病学量表评分呈正相关(r = 0.237;p < 0.01)。我们没有观察到 MHs 的存在与精神活性药物的使用之间存在显著关系(p > 0.05)。
我们表明,新诊断、未经治疗的 AD 和 aMCI 患者 MHs 的存在多于对照组。MHs 与其他行为症状和认知功能下降有关。我们建议对 MHs 进行具体询问,作为该人群的一个临床特征。